Navigation Links
ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
Date:3/29/2011

ifficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile infection.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events, including the therapeutic indication and use, safety, efficacy, tolerability and potential of our C1 esterase inhibitor and our focus, goals, strategy, research and development programs, and ability to develop pharmaceutical products, commercialize pharmaceutical products, and execute on our plans, including clinical development activities with C1 esterase inhibitor related to the treatment of acute antibody-mediated rejection. This is the first study of our C1 esterase inhibitor in the treatment of acute antibody-mediated rejection. There can be no assurance that that our phase 2 clinical program with C1 esterase inhibitor will yield positive results or support further development of C1 esterase inhibitor for treatment of acute antibody-mediated rejection. The FDA or EMA may view the data regarding utilization of C1 esterase inhibitor as treatment of acute antibody-mediated rejection as ins
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
2. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
3. ViroPharma Announces Securities Repurchase Program
4. ViroPharma to Participate in Two March Healthcare Conferences
5. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
6. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
7. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
8. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
9. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
10. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
11. ViroPharma To Participate in Two September Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... YORK, Feb. 17, 2011 Reportlinker.com ... report is available in its catalogue: ... 2016 - Cephalosporins, Penicillins, Macrolides and ... http://www.reportlinker.com/p0397051/Anti-Bacterials-Market-to-2016---Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market.html ...
... Reportlinker.com announces that a new market research ... Early Stage Drug Discovery in Disease Segments ... Gene Therapies http://www.reportlinker.com/p0397053/Early-Stage-Drug-Discovery-in-Disease-Segments---Innovation-Focuses-on-Stem-Cell-Therapies-and-Gene-Therapies.html ... Segments - Innovation Focuses on Stem Cell Therapies ...
Cached Medicine Technology:Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 2Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 3Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 2Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 3Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 4
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... Fox Chase Cancer Center paint a relatively optimistic picture ... cancers that have spread to the chest wall or ... into the skin, regardless of size and whether they ... III and called "locally advanced" tumors, suggesting that ... with poor survival. Locally advanced breast cancers of this ...
(Date:7/9/2014)... release is available in French . ... in 14 year old teens, including brain structure and function, ... accuracy who will go on to develop binge drinking within ... conscientiousness, and other variables such as life events and a ... binge drinking. Whether or not the child had had ...
(Date:7/9/2014)... It may smell of flatulence and have a reputation for ... dosage, hydrogen sulfide is now being being found to offer ... to stroke, heart attacks and dementia. A new compound (AP39), ... the key to future therapies, by targeting delivery of very ... places inside cells. , Scientists in Exeter have already ...
(Date:7/9/2014)... with kidney and heart disease have raised concerns about ... However, in the first study to look closely at ... at the University of Pennsylvania report that older kidney ... and cardiovascular health as very healthy older people who ... ever increasing organ transplant waitlists, the authors of the ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:What drives a child to abuse alcohol? 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... of fruit and vegetables are less likely to develop ... with chronic obstructive pulmonary disease (COPD) are smokers or ... COPD - so there must be influences that mitigate ... ,Researchers at the University of Southampton, UK, have ...
... consume wine in moderation have healthier lifestyles overall than abstainers ... well established that moderate alcohol consumption seems to confer ... of heart disease. A new study shows that it may ... produce at least some of the beneficial effects. ...
... that doctors know the power of a common heart medication ... many patients do not take the medications. Research shows the ... the risk of early death by 20 percent. However, many ... dysfunction and, therefore, do not take the drugs. A new ...
... the most widely spread cancer all over the world. ... expected to die from breast cancer this year. Researchers ... be an important factor fueling this ever-growing epidemic.// ... 25 countries that included information on breastfeeding and childbearing ...
... A commonly used antidepressant may help women who suffer ... citalopram, marketed as Celexa, may help women who have ... from the University of Pennsylvania Medical Center in Philadelphia, ... would work. Half-cycling means the medication is started 14 ...
... According to a new research, a daily dose of a ... the "bad", or LDL, cholesterol levels in young men. Functional ... supplying essential nutrients. //There has been a trend of adding ... healthier. For example, Benecol Spread is a margarine that contains ...
Cached Medicine News:Health News: Breastfeeding may decrease Breast Cancer Risk 2
EIA Kit for the detection of progesterone....
No cross-reaction with human pro-insulin and C-peptide....
... innovative GenePaint technology, the investigation of gene ... easier. The GenePaint system automates efficiently and ... required for performing ISH on cells or ... fixing, staining, washing and hybridization procedures. With ...
... (17alpha-OH-P) is a steroid produced in the ... defined physiological role except as a precursor ... be converted to cortisol by the sequential ... the adrenal glands and ovaries, 17alpha-OH-P can ...
Medicine Products: